Investors

Transgene (Euronext : TNG)

Transgene is a publicly traded French biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer.

Investor Relations Contact

Lucie Larguier, +33 (0)3 88 27 91 00

Key documents

brochure 2021
2021 registration document
Corporate presentation
Transgene in a nutshell

Contact Relations Investisseurs

Lucie Larguier, +33 (0)3 88 27 91 00

Financial information

Key figures

In € million except share and per share data 2021 2020 2019 2018 2017 2016
Revenue17.49.913.742.98.110.3
R&D Expense-32.9-27.3-31.4-27.3-30.4-26.4
G&A Expense-7.4-6.5-7.1-7.0-5.7-6.2
Net income (loss)-19.5-17.2-18.88.0-32.3-25.2
Net Cash Burn-10.0-17.0-20.5-24.5-28.1-30.6
Cash & Cash Equivalents49.626.343.316.941.456.2
Earnings/Loss per Share (Basic)-0.21-0.21-0.230.13-0.52-0.45
Earnings/Loss per Share (Diluted)-0.20-0.21-0.230.13-0.52-0.45
Shares Outstanding97,771,33483,841,33483,265,46462,275,92362,075,19056,431,991
Financial reports

YearsQuarterInterimRegistration Document
FirstSecondThirdFourth
2022      
2021       XBRL(fr)
2020      
2019      
2018      
2017      
2016      
2015        
2014      
Regulated information

Stock information

General

Stock price

Loading…

General

Stock MarketEuronext Paris – Eurolist (compartiment B)
Reuters / BloombergTRNG.PA / TNG.FP
ISIN CodeFR0005175080
Total number of shares outstanding97,771,334
Initial Public Offering (IPO)March 26, 1998
Local Sector IndexNext Biotech / CAC Mid 100
Financial Year EndsDecember 31

Analysts
CompanyAnalystE-mailPhone
Bryan Garnier & Co. LtdJean-Jacques Le Furjjlefur@bryangarnier.com+33 (0)1 70 36 57 45
Intron HealthNaresh Chouhannaresh@intronhealthresearch.com+44 207 375 9143
Invest SecuritiesJamila El Bougrinijelbougrini@invest-securities.com+33 (0)1 44 88 88 09
Kempen & Co.Suzanne van Voorthuizensuzanne.vanvoorthuizen@kempen.com+31 (0)20 348 8484
Kepler CheuvreuxArsene Guekam Kepler’s research can be accessed hereaguekam@keplercheuvreux.com+33 1 70 81 57 56
Life Science Capital LLCJacques A. Villefrancjacques@lifesciadvisors.com+1 646 597-6997
Oddo BHFMartial Descouturesmartial.descoutures@oddo-bhf.com+33 (0)1 44 51 85 00

Any opinions, forecasts, estimates, projections or predictions regarding Transgene’s performance made by the analysts are theirs alone and do not necessarily represent the opinions, forecasts, estimates, projections or predictions of Transgene or its management. By providing the names of the analysts or certain information from them, Transgene does not imply its endorsement of or concurrence with their reports, conclusions or recommendations. Transgene assumes no liability for the accuracy of such information and undertakes no obligation to update it.

Investor Events & Presentations

Financial calendar

  • November 4, 2021 - Third Quarter 2021 Financial Results
  • December 17, 2021 - Transgene announces investor Meeting for January 2022
  • March 16, 2022 - 2021 Fiscal Year Results
  • May 10, 2022 - First Quarter 2022 Financial Results
  • May 25, 2022 - Annual Shareholders’ Meeting
  • September 7, 2022 - First Half 2022 Financial Results
  • November 7, 2022 - Third Quarter 2022 Financial Results

Investor events

  • January 5, 2022 - 11th Annual LifeSci Advisors Corporate Access Event – Digital – January 5 to 7, 2022
  • January 6, 2022 - 25th ODDO BHF Digital Forum – Digital – January 6, 7, 10 and 11, 2022
  • January 10, 2022 - Biotech Showcase Investor Conference, in conjunction with the J.P. Morgan Healthcare conference – Digital – January 10 to 12, 2022
  • January 17, 2022 - Biotech Showcase Investor Conference – Digital- January 17 to 19, 2022
  • January 26, 2022 - Biomed Event – Paris
  • May 23, 2022 - UBS Global Healthcare Conference – New York
  • June 23, 2022 - Spring European MidCap Event – Paris – June 23 & 24, 2022
  • June 29, 2022 - Portzamparc Conference – Paris – June 29, 2022

Annual General Meeting

Annual General Meeting of May 25, 2022

2022 ORDINARY AND EXTRAORDINARY MEETING

 

Location TRANSGENE 400 boulevard Gonthier d’Andernach – Parc d’Innovation 67400 ILLKIRCH-GRAFFENSTADEN – FRANCE


Date and Time
25 May 2022 at 10 am – webcast (live and on-demand)

Documents

 

As pioneers in viral genome engineering, we have one ambition: To create innovative treatments to fight cancers.

Transgene sa
400 Boulevard Gonthier d’Andernach - Parc d'Innovation - CS80166
67405 Illkirch Graffenstaden Cedex - France |
Tel. : + 33 (0) 3 88 27 91 00

 

© 2021 Transgene - All rights reserved
Terms of use - Credits